ADDITIONAL SOUTHERN CALIFORNIA BREAST HEALTH CENTERS ADD DIGNICAP® TO THEIR PATIENT TREATMENT OFFERINGS

Lund, Sweden—October 4, 2016—Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in 2015 by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all five Breastlink centers in the U.S.  The DigniCap® system is the first and only scalp cooling device to complete rigorous FDA clinical trials in America, where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair.

On the heels of the FDA Clearance, medical centers across the country have begun offering the DigniCap® scalp cooling system as part of the comprehensive cancer care treatment services they provide. Through funding from a recent Private Placement and Rights Offering, Dignitana’s US presence is rapidly expanding as demand for the medical device accelerates. Breastlink, a comprehensive breast health center with five locations in Southern California will be offering DigniCap® scalp cooling systems as part of their breast cancer treatment and care regimens. Breastlink offers women a comprehensive breast cancer risk assessment program to help empower them about their health care options.

DigniCap® scalp cooling system will be offered in all of the Breastlink Health Centers. Locations are as follows:

• Breastlink Laguna Hills, California

• Breastlink Temecula Valley, California

• Breastlink Newport Beach, California

• Breastlink Orange, California

• Breastlink Encino, California

“We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago,” said Jan Richardsson, Chief Executive Officer of Dignitana. “The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.”

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

För ytterligare information vänligen kontakta:

Jan Richardsson
VD, Dignitana AB (publ)

Telefon: 046-16 30 92
E-post: jan.richardsson@dignitana.se

Om Dignitana AB (publ)
Dignitanas, med säte i Lund, affärsidé är att utveckla, tillverka och marknadsföra den medicintekniska produkten DigniCap®. Dignitana bedriver en kontinuerlig forskning och utveckling av nya användningsområden för DigniCap®. Dignitanas aktier handlas på NASDAQ OMX First North med Erik Penser Bank som Certified Adviser. För mer information gå in på: www.dignitana.se

Om skalpkylningssystemet DigniCap®
Dignitanas huvudprodukt - skalpkylningssystemet DigniCap® - är ett patenterat system med syfte att eliminera eller kraftigt reducera håravfall för patienter som genomgår cytostatikabehandling. DigniCap® erbjuder skalpkylning med jämn kyla, hög effektivitet, säkerhet och acceptabel komfort.

Taggar: